<DOC>
	<DOCNO>NCT00997789</DOCNO>
	<brief_summary>The aim study evaluate pharmacokinetic property bioequivalence two rebamipide preparation healthy Korean male volunteer generic substitution evaluate association genetic polymorphism ABCB1 gene ( exon 21 26 ) rebamipide disposition .</brief_summary>
	<brief_title>Bioequivalence Rebamipide Korean</brief_title>
	<detailed_description>A randomized , single-dose , 2-period crossover design 7-day washout period conduct 30 healthy Korean male volunteer . Subjects randomly assign receive single 100-mg dose test reference preparation rebamipide , administer 240 mL water 12-hour overnight fast . All subject select pass clinical screening procedure include physical examination laboratory test . Serum concentration rebamipide 12 hour administration determine use validate HPLC method fluorescence detection . Adverse event ( AEs ) continuously monitor clinical staff via observation , personal interview , vital sign ( temperature , blood pressure , heart rate ) study period . All adverse event record clinical record form per subject 1 week study . Pharmacokinetic parameter determine use noncompartmental method . The preparation consider bioequivalent log-transformed ratio AUC0-t , AUC0-âˆž , Cmax within predetermine bioequivalence range ( ie , 80-125 % ) , set US Food Drug Administration ( FDA ) Korean legislation . In vitro dissolution profile preparation examine influence genetic polymorphism ABCB1 gene ( P-glycoprotein ) pharmacokinetics rebamipide also investigate .</detailed_description>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>Subjects select pass clinical screening procedure include physical examination laboratory test ( blood analysis ; hemoglobin , hematocrit , RBC , WBC , platelet , differential counting WBC , total protein , albumin , ALT , AST , alkaline phosphatase , total bilirubin , cholesterol , creatinine , blood urea nitrogen , fast glucose urine analysis ; specific gravity , color , pH , sugar , albumin , bilirubin , RBC , WBC cast ) . Subjects possibly sensitive type preparation , Subjects history hepatic illness , Subjects history renal illness , Subjects history respiratory illness , Subjects history endocrine illness , Subjects history cardiovascular system illness , Subjects take alcohol within 4 week prior study , Subjects take preparation within 4 week prior study .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Rebamipide</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>ABCB1 genetic polymorphism</keyword>
</DOC>